Tags

Type your tag names separated by a space and hit enter

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Diagn Microbiol Infect Dis. 2005 Jul; 52(3):181-6.DM

Abstract

The activity of tigecycline (formerly GAR936), a novel glycylcycline, was tested against recent bloodstream infection (BSI) pathogen isolates from 6 continents. Frequency of clinical occurrence of these pathogens was determined and their antibiograms assessed using reference broth microdilution methods. A total of 26474 strains were tested for tigecycline susceptibility according to the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) by the M7-A6 guidelines with interpretations from M100-S15 and the package insert. The rank order of pathogens was Staphylococcus aureus (33.1%), Escherichia coli (14.0%), coagulase-negative staphylococci (13.5%), Enterococcus spp. (12.3%), Klebsiella spp. (5.7%), Pseudomonas aeruginosa (4.2%), Enterobacter spp. (3.0%), beta-hemolytic streptococci (2.9%), Streptococcus pneumoniae (2.3%), and viridans group streptococci (1.4%). Tigecycline exhibited a broader spectrum of activity against BSI isolates when compared to ciprofloxacin, tetracycline, aminoglycosides, and many beta-lactams (imipenem). Tigecycline was highly active against most pathogens tested, including staphylococci (MIC(90), 0.5 microg/mL), enterococci (MIC90, 0.25 microg/mL), streptococci (MIC(90), < or =0.12 microg/mL), Escherichia coli (MIC90, 0.25 microg/mL), Klebsiella spp. (MIC90, 1 mmicrog/mL), and Enterobacter spp. (MIC(90), 2 mmicrog/mL), but showed limited inhibition of Pseudomonas aeruginosa (MIC90, 16 microg/mL) and indole-positive or indole-negative Proteae (MIC90, 4-8 microg/mL). In summary, tigecycline exhibited a wide spectrum of antimicrobial potency versus BSI isolates collected worldwide. Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA 52317, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16105562

Citation

Sader, Helio S., et al. "Tigecycline Activity Tested Against 26,474 Bloodstream Infection Isolates: a Collection From 6 Continents." Diagnostic Microbiology and Infectious Disease, vol. 52, no. 3, 2005, pp. 181-6.
Sader HS, Jones RN, Stilwell MG, et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52(3):181-6.
Sader, H. S., Jones, R. N., Stilwell, M. G., Dowzicky, M. J., & Fritsche, T. R. (2005). Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagnostic Microbiology and Infectious Disease, 52(3), 181-6.
Sader HS, et al. Tigecycline Activity Tested Against 26,474 Bloodstream Infection Isolates: a Collection From 6 Continents. Diagn Microbiol Infect Dis. 2005;52(3):181-6. PubMed PMID: 16105562.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. AU - Sader,Helio S, AU - Jones,Ronald N, AU - Stilwell,Matthew G, AU - Dowzicky,Michael J, AU - Fritsche,Thomas R, PY - 2005/05/25/accepted PY - 2005/8/18/pubmed PY - 2006/1/13/medline PY - 2005/8/18/entrez SP - 181 EP - 6 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 52 IS - 3 N2 - The activity of tigecycline (formerly GAR936), a novel glycylcycline, was tested against recent bloodstream infection (BSI) pathogen isolates from 6 continents. Frequency of clinical occurrence of these pathogens was determined and their antibiograms assessed using reference broth microdilution methods. A total of 26474 strains were tested for tigecycline susceptibility according to the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) by the M7-A6 guidelines with interpretations from M100-S15 and the package insert. The rank order of pathogens was Staphylococcus aureus (33.1%), Escherichia coli (14.0%), coagulase-negative staphylococci (13.5%), Enterococcus spp. (12.3%), Klebsiella spp. (5.7%), Pseudomonas aeruginosa (4.2%), Enterobacter spp. (3.0%), beta-hemolytic streptococci (2.9%), Streptococcus pneumoniae (2.3%), and viridans group streptococci (1.4%). Tigecycline exhibited a broader spectrum of activity against BSI isolates when compared to ciprofloxacin, tetracycline, aminoglycosides, and many beta-lactams (imipenem). Tigecycline was highly active against most pathogens tested, including staphylococci (MIC(90), 0.5 microg/mL), enterococci (MIC90, 0.25 microg/mL), streptococci (MIC(90), < or =0.12 microg/mL), Escherichia coli (MIC90, 0.25 microg/mL), Klebsiella spp. (MIC90, 1 mmicrog/mL), and Enterobacter spp. (MIC(90), 2 mmicrog/mL), but showed limited inhibition of Pseudomonas aeruginosa (MIC90, 16 microg/mL) and indole-positive or indole-negative Proteae (MIC90, 4-8 microg/mL). In summary, tigecycline exhibited a wide spectrum of antimicrobial potency versus BSI isolates collected worldwide. Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/16105562/Tigecycline_activity_tested_against_26474_bloodstream_infection_isolates:_a_collection_from_6_continents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(05)00132-X DB - PRIME DP - Unbound Medicine ER -